- Home
- CAVA vs ICLR Comparison
CAVA vs ICLR Comparison
Compare CAVA & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAVA
- ICLR
- Stock Information
- Founded
- CAVA 2006
- ICLR 1990
- Country
- CAVA United States
- ICLR Ireland
- Employees
- CAVA N/A
- ICLR N/A
- Industry
- CAVA Restaurants
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- Sector
- CAVA Consumer Discretionary
- ICLR Health Care
- Exchange
- CAVA Nasdaq
- ICLR Nasdaq
- Market Cap
- CAVA 16.2B
- ICLR 15.7B
- IPO Year
- CAVA 2023
- ICLR 1998
- Fundamental
- Price
- CAVA $141.37
- ICLR $189.64
- Analyst Decision
- CAVA Buy
- ICLR Strong Buy
- Analyst Count
- CAVA 14
- ICLR 10
- Target Price
- CAVA $144.77
- ICLR $294.50
- AVG Volume (30 Days)
- CAVA 2.9M
- ICLR 2.1M
- Earning Date
- CAVA 11-12-2024
- ICLR 10-23-2024
- Dividend Yield
- CAVA N/A
- ICLR N/A
- EPS Growth
- CAVA N/A
- ICLR 44.49
- EPS
- CAVA 0.46
- ICLR 8.99
- Revenue
- CAVA $913,488,000.00
- ICLR $8,306,823,000.00
- Revenue This Year
- CAVA $31.31
- ICLR $4.00
- Revenue Next Year
- CAVA $21.34
- ICLR $3.16
- P/E Ratio
- CAVA $301.39
- ICLR $21.10
- Revenue Growth
- CAVA 34.05
- ICLR 3.63
- 52 Week Low
- CAVA $31.47
- ICLR $188.57
- 52 Week High
- CAVA $172.43
- ICLR $347.72
- Technical
- Relative Strength Index (RSI)
- CAVA 56.64
- ICLR 17.52
- Support Level
- CAVA $143.24
- ICLR $208.65
- Resistance Level
- CAVA $172.43
- ICLR $217.91
- Average True Range (ATR)
- CAVA 6.90
- ICLR 8.02
- MACD
- CAVA -0.04
- ICLR -1.46
- Stochastic Oscillator
- CAVA 27.64
- ICLR 2.32
About CAVA CAVA Group Inc.
Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates the majority of its revenue from the CAVA segment.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.